549 related articles for article (PubMed ID: 34583655)
1. Macrophages and cancer stem cells: a malevolent alliance.
Allavena P; Digifico E; Belgiovine C
Mol Med; 2021 Sep; 27(1):121. PubMed ID: 34583655
[TBL] [Abstract][Full Text] [Related]
2. Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.
Müller L; Tunger A; Plesca I; Wehner R; Temme A; Westphal D; Meier F; Bachmann M; Schmitz M
Front Immunol; 2020; 11():140. PubMed ID: 32117287
[TBL] [Abstract][Full Text] [Related]
3. Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells.
Luo S; Yang G; Ye P; Cao N; Chi X; Yang WH; Yan X
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740975
[TBL] [Abstract][Full Text] [Related]
4. Influence of Innate Immunity on Cancer Cell Stemness.
Pastò A; Consonni FM; Sica A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397392
[TBL] [Abstract][Full Text] [Related]
5. Immune modulation by a cellular network of mesenchymal stem cells and breast cancer cell subsets: Implication for cancer therapy.
Eltoukhy HS; Sinha G; Moore CA; Sandiford OA; Rameshwar P
Cell Immunol; 2018 Apr; 326():33-41. PubMed ID: 28779846
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche.
Rajayi H; Tavasolian P; Rezalotfi A; Ebrahimi M
Int Rev Immunol; 2019; 38(6):267-283. PubMed ID: 31578892
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs: As Critical Regulators of Tumor- Associated Macrophages.
Chatterjee B; Saha P; Bose S; Shukla D; Chatterjee N; Kumar S; Tripathi PP; Srivastava AK
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992449
[TBL] [Abstract][Full Text] [Related]
8. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
Front Immunol; 2021; 12():656364. PubMed ID: 34122412
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies.
Sainz B; Carron E; Vallespinós M; Machado HL
Mediators Inflamm; 2016; 2016():9012369. PubMed ID: 26980947
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between M2 macrophages and glioma stem cells.
Nusblat LM; Carroll MJ; Roth CM
Cell Oncol (Dordr); 2017 Oct; 40(5):471-482. PubMed ID: 28643230
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell-immune cell crosstalk in tumour progression.
Bayik D; Lathia JD
Nat Rev Cancer; 2021 Aug; 21(8):526-536. PubMed ID: 34103704
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.
Li K; Nie H; Jin R; Wu X
Front Immunol; 2024; 15():1397005. PubMed ID: 38779660
[TBL] [Abstract][Full Text] [Related]
13. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?
Plaks V; Kong N; Werb Z
Cell Stem Cell; 2015 Mar; 16(3):225-38. PubMed ID: 25748930
[TBL] [Abstract][Full Text] [Related]
14. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
15. Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?
Vahidian F; Duijf PHG; Safarzadeh E; Derakhshani A; Baghbanzadeh A; Baradaran B
Immunol Lett; 2019 Apr; 208():19-29. PubMed ID: 30862442
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cells, CD200 and immunoevasion.
Kawasaki BT; Farrar WL
Trends Immunol; 2008 Oct; 29(10):464-8. PubMed ID: 18775673
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages derived from cancer stem cells.
Osman A; Oze M; Afify SM; Hassan G; El-Ghlban S; Nawara HM; Fu X; Zahra MH; Seno A; Winer I; Salomon DS; Seno M
Acta Histochem; 2020 Dec; 122(8):151628. PubMed ID: 32992123
[TBL] [Abstract][Full Text] [Related]
18. The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.
Asiry S; Kim G; Filippou PS; Sanchez LR; Entenberg D; Marks DK; Oktay MH; Karagiannis GS
Front Immunol; 2021; 12():654877. PubMed ID: 33927723
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression.
Ma Y; Lv H; Xing F; Xiang W; Wu Z; Feng Q; Wang H; Yang W
Front Med; 2024 Jun; 18(3):430-445. PubMed ID: 38600350
[TBL] [Abstract][Full Text] [Related]
20. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
